Gene: ADAMTS19

171019
-
ADAM metallopeptidase with thrombospondin type 1 motif 19
protein-coding
5q23.3
Ensembl:ENSG00000145808 MIM:607513 Vega:OTTHUMG00000128990 UniprotKB:Q8TE59
NC_000005.10
PubMed
0   ANCO-SNPs
ND
1   
NA (AD)  NA (ND)   (Frontal_Cortex)
3.255e-1 (AD)  8.150e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
PASK0.782
OCA20.778
RAP1GAP0.775
SORCS30.771
IGSF220.77
RYR20.768
CSMD20.761
GREM20.76
ZNF6670.755
SORCS10.754

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
COPZ2-0.474
ASB4-0.452
NXT2-0.437
MAPKAPK3-0.433
ZIC2-0.417
PHYHD1-0.412
MBNL3-0.408
PARD3B-0.4
MSX1-0.396
YES1-0.395

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with methylmercuric chloride co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAMTS19 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAMTS19 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAMTS19 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAMTS19 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAMTS19 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with methylmercuric chloride co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAMTS19 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAMTS19 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAMTS19 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAMTS19 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAMTS19 mRNA"27188386
D016604Aflatoxin B1Aflatoxin B1 results in decreased methylation of ADAMTS19 gene27153756
D018501Antirheumatic AgentsAntirheumatic Agents results in increased expression of ADAMTS19 mRNA24449571
D001280AtrazineAtrazine results in decreased expression of ADAMTS19 mRNA22378314
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of ADAMTS19 mRNA22228805
D0151237,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide"7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in increased expression of ADAMTS19 mRNA"20382639
D004958EstradiolEstradiol results in increased expression of ADAMTS19 mRNA19484750
C006780bisphenol Abisphenol A results in decreased expression of ADAMTS19 mRNA25181051
D003042CocaineCocaine results in decreased expression of ADAMTS19 mRNA27899881
D003300CopperCopper deficiency results in increased expression of ADAMTS19 mRNA26033743
D019422Dietary SucroseDietary Sucrose results in increased expression of ADAMTS19 mRNA26033743
D006861Hydrogen PeroxideHydrogen Peroxide affects the expression of ADAMTS19 mRNA20044591
C561695(+)-JQ1 compound(+)-JQ1 compound results in decreased expression of ADAMTS19 mRNA26752646
C004925methylmercuric chloridemethylmercuric chloride results in decreased expression of ADAMTS19 mRNA23179753
C004925methylmercuric chloridemethylmercuric chloride results in increased expression of ADAMTS19 mRNA23179753|2627250
C004925methylmercuric chloride"[NOG protein co-treated with methylmercuric chloride co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAMTS19 mRNA"27188386
C496932panobinostat"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAMTS19 mRNA"27188386
C496932panobinostatpanobinostat results in increased expression of ADAMTS19 mRNA26272509
C046012pentanalpentanal results in increased expression of ADAMTS19 mRNA26079696
C005556propionaldehydepropionaldehyde results in decreased expression of ADAMTS19 mRNA26079696
D011441PropylthiouracilPropylthiouracil results in increased expression of ADAMTS19 mRNA24780913
D014212TretinoinTretinoin results in increased expression of ADAMTS19 mRNA21934132
C012589trichostatin A"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAMTS19 mRNA"27188386
C012589trichostatin Atrichostatin A results in increased expression of ADAMTS19 mRNA24935251|2627250
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAMTS19 mRNA"27188386
D014635Valproic AcidValproic Acid affects the expression of ADAMTS19 mRNA25979313
D014635Valproic AcidValproic Acid results in increased expression of ADAMTS19 mRNA23179753|2438349
C111237vorinostat"[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAMTS19 mRNA"27188386

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0004222metalloendopeptidase activity-IEA-  
GO:0046872metal ion binding-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0006508proteolysis-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005576extracellular region-IEA-  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence
R-HSA-1643685DiseaseTAS
R-HSA-3781865Diseases of glycosylationTAS
R-HSA-3906995Diseases associated with O-glycosylation of proteinsTAS
R-HSA-392499Metabolism of proteinsTAS
R-HSA-5083635Defective B3GALTL causes Peters-plus syndrome (PpS)TAS
R-HSA-5173105O-linked glycosylationTAS
R-HSA-5173214O-glycosylation of TSR domain-containing proteinsTAS
R-HSA-597592Post-translational protein modificationTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
22837378Genome-wide association studies identify CHRNA5/3 and HTR4 in the development of airflow obstruction. (2012 Oct 1)Wilk JBAm J Respir Crit Care Med